Showing results (61-70 of 125) with videos related to
Sort By:
Pageof 13
Investigational New Drugs|October 21, 2010
Trabectedin in pre-treated patients with advanced or metastatic soft tissue sarcoma: a phase II study evaluating co-treatment with dexamethasoneLuis Paz-Ares, Antonio López-Pousa, Andrés Poveda, et al.Ecancermedicalscience|February 23, 2019
Proteomics characterisation of central nervous system metastasis biomarkers in triple negative breast cancerKaterin Rojas L, Lucía Trilla-Fuertes, Angelo Gámez-Pozo, et al.The Oncologist|April 27, 2019
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast CancerEva Ciruelos, María Apellániz-Ruiz, Blanca Cantos, et al.Breast Cancer Research and Treatment|August 10, 2020
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory studyFrancesco Schettini, Navid Sobhani, Anna Ianza, et al.Breast Cancer Research and Treatment|August 20, 2021
Full population results from the core phase of CompLEEment-1, a phase 3b study of ribociclib plus letrozole as first-line therapy for advanced breast cancer in an expanded populationMichelino De Laurentiis, Simona Borstnar, Mario Campone, et al.European Journal of Cancer (Oxford, England : 1990)|September 6, 2022
Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trialGuillermo Villacampa, Claudette Falato, Laia Paré, et al.Journal of Breast Imaging|November 3, 2025
Vacuum-assisted Biopsy and Surgical Correlation in HER2-positive and Triple-Negative Breast Cancer Subtypes in MRI Responders After Neoadjuvant Systemic Therapy. BISUCO TRIALSara Jimenez Arranz, Fernando Pizarro, Maria Angeles Fernandez Matamoros, et al.ESC Heart Failure|February 2, 2022
Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parametersBelén Díaz-Antón, Rodrigo Madurga, Blanca Zorita, et al.Lancet (London, England)|February 2, 2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohortLuca Gianni, Wolfgang Eiermann, Vladimir Semiglazov, et al.Lancet (London, England)|August 26, 2023
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trialHope S Rugo, Aditya Bardia, Frederik Marmé, et al.Pageof 13